Literature DB >> 23452563

Effects of acute detoxification of the herbal blend 'Spice Gold' on dopamine D2/3 receptor availability: a [18F]fallypride PET study.

Axel Rominger1, Paul Cumming, Guoming Xiong, Gabriele Koller, Stefan Förster, Andreas Zwergal, Evangelos Karamatskos, Peter Bartenstein, Christian La Fougère, Oliver Pogarell.   

Abstract

We carried out dynamic [(18)F]fallypride PET scans to measure cerebral dopamine D2/3 receptor availability in a 23-year old patient experiencing a severe withdrawal syndrome upon voluntary abstinence from "Spice", a pre-packaged herbal smoking thought to contain synthetic cannabinoids. Upon admission to the clinic, the patient experienced craving, affective symptoms and a range of somatic complaints, which resolved after several days' monitored abstinence. PET scans were performed on the day of admission, and one week later. Estimates of [(18)F]fallypride binding potential (BPND) were obtained in striatal and extrastriatal brain regions, and compared to results of age-matched healthy control subjects. Upon admission, [(18)F]fallypride BPND was reduced by 20% in the patient's striatum and also in extra-striatal regions. During short-term follow-up upon detoxification, the BPND increased to normal values. This study shows substantial short-term alterations of dopamine D2/3 receptor availability in a patient before and after acute detoxification from "Spice Gold", thus providing first evidence of reversible effects on dopamine receptors of heavy use of a herbal smoking blend.
Copyright © 2013 Elsevier B.V. and ECNP. All rights reserved.

Entities:  

Keywords:  Addiction; Cannabinoid; Dopamine D(2/3) receptor; PET; Spice

Mesh:

Substances:

Year:  2013        PMID: 23452563     DOI: 10.1016/j.euroneuro.2013.01.009

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  8 in total

Review 1.  Synthetic cannabinoids 2015: An update for pediatricians in clinical practice.

Authors:  Daniel Castellanos; Leonard M Gralnik
Journal:  World J Clin Pediatr       Date:  2016-02-08

2.  Novel psychoactive substances of interest for psychiatry.

Authors:  Fabrizio Schifano; Laura Orsolini; G Duccio Papanti; John M Corkery
Journal:  World Psychiatry       Date:  2015-02       Impact factor: 49.548

Review 3.  Spicing things up: synthetic cannabinoids.

Authors:  Max Spaderna; Peter H Addy; Deepak Cyril D'Souza
Journal:  Psychopharmacology (Berl)       Date:  2013-07-09       Impact factor: 4.530

4.  Chronic Synthetic Marijuana Use: A Case of First-Onset Seizures as a Withdrawal Symptom.

Authors:  Amber N Edinoff; Prithvi Doppalapudi; Juliana M Fort
Journal:  Health Psychol Res       Date:  2022-04-26

Review 5.  Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications.

Authors:  Marisol S Castaneto; David A Gorelick; Nathalie A Desrosiers; Rebecca L Hartman; Sandrine Pirard; Marilyn A Huestis
Journal:  Drug Alcohol Depend       Date:  2014-08-18       Impact factor: 4.492

Review 6.  Synthetic Cathinone and Cannabinoid Designer Drugs Pose a Major Risk for Public Health.

Authors:  Aviv M Weinstein; Paola Rosca; Liana Fattore; Edythe D London
Journal:  Front Psychiatry       Date:  2017-08-23       Impact factor: 4.157

Review 7.  Emerging drugs of abuse: current perspectives on synthetic cannabinoids.

Authors:  Danièle Debruyne; Reynald Le Boisselier
Journal:  Subst Abuse Rehabil       Date:  2015-10-20

Review 8.  Synthetic and Non-synthetic Cannabinoid Drugs and Their Adverse Effects-A Review From Public Health Prospective.

Authors:  Koby Cohen; Aviv M Weinstein
Journal:  Front Public Health       Date:  2018-06-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.